Laia Josa-Culleré

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 12

Top Venues

Journal of medicinal chemistry

ChemMedChem

RSC medicinal chemistry

The Journal of organic chemistry

University of Oxford

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Oxford

United Kingdom

Postdoctoral Fellow

Publications

Michele Mari, Caroline Lanthier, Matic Proj, Etienne J Donckele, Laia Josa-Culleré, Kristina Goncharenko, Salomé Leroy, Brieuc Matagne, Sean M McKenna, Chiara Borsari
Boosting the Impact of EFMC Young Scientists Network Through the Creation of Working Groups. ChemMedChem (2024)
Thomas J Cogswell, Laia Josa-Culleré, David Zimmer, Sébastien R G Galan, Morgan Jay-Smith, Katrina S Madden, Carole J R Bataille, Thomas R Jackson, Douzi Zhang, Stephen G Davies, Paresh Vyas, Thomas A Milne, Graham M Wynne, Angela J Russell
Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia. RSC medicinal chemistry (2024)
Thomas J Cogswell, Laia Josa-Culleré, David Zimmer, Sébastien R G Galan, Morgan Jay-Smith, Katrina S Madden, Carole J R Bataille, Thomas R Jackson, Douzi Zhang, Stephen G Davies, Paresh Vyas, Thomas A Milne, Graham M Wynne, Angela J Russell
Lead optimisation of OXS007417: in vivo PK profile and hERG liability modulation to optimise a small molecule differentiation agent for the potential treatment of acute myeloid leukaemia. RSC medicinal chemistry (2024)
Michele Mari, Caroline Lanthier, Matic Proj, Etienne J Donckele, Laia Josa-Culleré, Kristina Goncharenko, Salomé Leroy, Brieuc Matagne, Sean M McKenna, Chiara Borsari
Boosting the Impact of EFMC Young Scientists Network Through the Creation of Working Groups. ChemMedChem 19 (15) (2024)
Laia Josa-Culleré, Amadeu Llebaria
Visible-Light-Controlled Histone Deacetylase Inhibitors for Targeted Cancer Therapy. Journal of medicinal chemistry (2023)
Laia Josa-Culleré, Amadeu Llebaria
Visible-Light-Controlled Histone Deacetylase Inhibitors for Targeted Cancer Therapy. Journal of medicinal chemistry 66 (3) (2023)
Laia Josa-Culleré, Amadeu Llebaria
Visible-Light-Controlled Histone Deacetylase Inhibitors for Targeted Cancer Therapy. Journal of medicinal chemistry 66 (3) (2023)
Laia Josa-Culleré, Amadeu Llebaria
Visible-Light-Controlled Histone Deacetylase Inhibitors for Targeted Cancer Therapy. Journal of medicinal chemistry 66 (3) (2023)
Laia Josa-Culleré, Amadeu Llebaria
Visible-Light-Controlled Histone Deacetylase Inhibitors for Targeted Cancer Therapy. Journal of medicinal chemistry 66 (3) (2023)
Laia Josa-Culleré, Amadeu Llebaria
Visible-Light-Controlled Histone Deacetylase Inhibitors for Targeted Cancer Therapy. Journal of medicinal chemistry 66 (3) (2023)
Laia Josa-Culleré, Thomas J Cogswell, Irene Georgiou, Morgan Jay-Smith, Thomas R Jackson, Carole J R Bataille, Stephen G Davies, Paresh Vyas, Thomas A Milne, Graham M Wynne, Angela J Russell
Identification and Preliminary Structure-Activity Relationship Studies of 1,5-Dihydrobenzo[e][1,4]oxazepin-2(3H)-ones That Induce Differentiation of Acute Myeloid Leukemia Cells In Vitro. Molecules (Basel, Switzerland) 26 (21) (2021)
Laia Josa-Culleré, Michael G Hirst, Jonathan P Lockett, Amber L Thompson, Mark G Moloney
Spirocyclic Tetramates by Sequential Knoevenagel and [1,5]-Prototropic Shift. The Journal of organic chemistry 84 (15) (2019)

Laia Josa-Culleré.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Laia Josa-Culleré